1-6 of 6
Jens Kisro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3047.
https://doi.org/10.1182/blood-2019-131025
Published: 2019
Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3035.
https://doi.org/10.1182/blood-2019-123419
Published: 2019
Journal Articles

Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany

Carl C. Crodel, Kathleen Jentsch-Ulrich, MD, Lutz Jacobasch, Philipp Kiewe, Jens Kisro, Jörg Lipke, Siegfried W. Prenninger, Marcel Reiser, Regine Wunschel, Andreas Hochhaus, MD, Florian H. Heidel
Journal: Blood
Blood (2019) 134 (Supplement_1): 1672.
https://doi.org/10.1182/blood-2019-122681
Published: 2019
Journal Articles

Safety of Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Results from the Primary Analysis of the Phase 3b GREEN Study

Stephan Stilgenbauer, MD PhD, Melih Aktan, Christelle M Ferra Coll, Caroline Dartigeas, Jens Kisro, Marco Montillo, MD, João Raposo, Jean-Louis Merot, Susan Robson, Ekaterina Gresko, Francesc Bosch, Robin Foà, MD, Véronique Leblond
Journal: Blood
Blood (2017) 130 (Supplement 1): 4309.
https://doi.org/10.1182/blood.V130.Suppl_1.4309.4309
Published: 2017
Journal Articles

Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study

Francesc Bosch, Robin Foà, Agostino Cortelezzi, MD, Jens Kisro, Veronique Leblond, Gayane Tumyan, Ekaterina Gresko, Susan Robson, Stephan Stilgenbauer
Journal: Blood
Blood (2016) 128 (22): 5589.
https://doi.org/10.1182/blood.V128.22.5589.5589
Published: 2016
Journal Articles

Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).

Andreas Josting, MD, Christian Rudolph, MD, Markus Mapara, MD, Jan-Peter Glossmann, MD, Markus Sieber, MD, Hartmut H. Kirchner, MD, Bernd Dörken, MD, Dieter K. Hossfeld, MD, Jens Kisro, MD, Bernd Metzner, MD, Wolfgang E. Berdel, MD, Volker Diehl, MD, Andreas Engert, MD
Journal: Blood
Blood (2004) 104 (11): 309.
https://doi.org/10.1182/blood.V104.11.309.309
Published: 2004